• Follow
  • Follow
  • Follow
  • Follow
  • Follow

Tel: +1 (844) 792-6300

  • Products
    • Product Overview
    • BASHIR™ Endovascular Catheter
    • BASHIR™ S-B Endovascular Catheter
    • BASHIR™ Plus Endovascular Catheter
  • Clinical Resources
    • Clinical Data
    • Clinical Library
    • Webinars & Events
    • Instructions For Use
    • Value Analysis
  • Patient Resources
  • News
  • About Us
  • Contact
First Patient Enrolled In Thrombolex’s RESCUE II Study — On-Table Pharmacomechanical Lysis Without Post-Procedural Infusion 

First Patient Enrolled In Thrombolex’s RESCUE II Study — On-Table Pharmacomechanical Lysis Without Post-Procedural Infusion 

by Thrombolex | Jan 22, 2024 | News

NEW BRITAIN, PA (January 22, 2024) Thrombolex, Inc. announced the enrollment of the first patient in the RESCUE II study using the BASHIR™ Endovascular Catheter for the treatment of acute intermediate-risk pulmonary embolism by Drs. Riyaz Bashir and Vladimir Lakhter,...
Thrombolex, Inc. Announces the New BASHIR™ .035″ Endovascular Catheters, Now Compatible with a 0.035″ Guidewire for the Treatment of Acute Pulmonary Embolism

Thrombolex, Inc. Announces the New BASHIR™ .035″ Endovascular Catheters, Now Compatible with a 0.035″ Guidewire for the Treatment of Acute Pulmonary Embolism

by Thrombolex | Jan 9, 2024 | News

NEW BRITAIN, PA (January 9, 2024) Thrombolex, Inc., a medical device company that develops innovative devices for the treatment of arterial and venous thromboembolic diseases, announces an expansion of the existing product line with the new BASHIR™ .035 and BASHIR™...
Significant New Insights from the NIH-Sponsored RESCUE Trial with the BASHIR™ Endovascular Catheter Published in JACC: Advances. 

Significant New Insights from the NIH-Sponsored RESCUE Trial with the BASHIR™ Endovascular Catheter Published in JACC: Advances. 

by Thrombolex | Oct 24, 2023 | News

NEW BRITAIN, PA (October 24, 2023) Thrombolex, Inc., a medical device company focused on developing innovative products for the treatment of arterial and venous thromboembolic diseases, announced never-before-reported major reductions in obstruction in all of the...
Thrombolex Receives 510(k) Clearance for Treatment of Acute Pulmonary Embolism

Thrombolex Receives 510(k) Clearance for Treatment of Acute Pulmonary Embolism

by Thrombolex | Apr 20, 2023 | News

NEW BRITAIN, PA – April 20, 2023 – Thrombolex, Inc. has received 510(k) clearance for use of the BASHIR™ and BASHIR™ S-B Endovascular Catheters for the treatment of acute pulmonary embolism (PE). This PE specific clearance was based upon the positive results from the...
Marked reduction in segmental and main pulmonary artery occlusions shown in NIH-funded RESCUE Trial

Marked reduction in segmental and main pulmonary artery occlusions shown in NIH-funded RESCUE Trial

by Thrombolex | Mar 7, 2023 | News

Marked reduction in segmental and main pulmonary artery occlusions shown in NIH-sponsored RESCUE trial with the BASHIR™ Endovascular Catheter in Patients with Intermediate Risk Acute Pulmonary Embolism NEW BRITAIN, PA (March 6, 2023). Robert A. Lookstein MD, Executive...
Thrombolex, Inc., Awarded 2-Year Agreement with Premier, Inc. for Hybrid Endovascular Catheter

Thrombolex, Inc., Awarded 2-Year Agreement with Premier, Inc. for Hybrid Endovascular Catheter

by Thrombolex | Dec 15, 2022 | News

NEW BRITAIN, PA (December 15, 2022) Thrombolex, Inc. has been awarded a group purchasing agreement with Premier Inc. effective December 1, 2022. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms...
« Older Entries
Next Entries »

Recent Posts

  • Thrombolex Secures $50M Series A Financing to Advance Endovascular Treatment for Pulmonary Embolism and Venous Thrombus
  • Interim Data from the RAPID-PE Study Presented at TCT 2025
  • RESCUE-II Study results published in JACC: Advances
  • Rescue II Results
  • RAPID-PE Study News

Recent Comments

No comments to show.

Call Today:

Tel: +1 (844) 792-6300

Email:

orders@thrombolex.com

info@thrombolex.com

Quick Links:

  • Products
  • Clinical Library
  • Patient Resources
  • News
  • About Us
  • Contact
  • Follow
  • Follow
  • Follow
  • Follow

© 2024 by Thrombolex™   ·   All Rights Reserved   ·   Disclaimers   ·   Patents   ·   Privacy Policy 

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}